Gevokizumab

Generic Name
Gevokizumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1129435-60-4
Unique Ingredient Identifier
QX3JU54GYQ
Background

Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Phase 2
Completed
Conditions
Pyoderma Gangrenosum
Interventions
Drug: gevokizumab
First Posted Date
2013-06-20
Last Posted Date
2016-02-03
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
8
Registration Number
NCT01882504

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Phase 2
Completed
Conditions
Osteoarthritis
Interventions
Drug: Placebo
Drug: gevokizumab
First Posted Date
2012-09-11
Last Posted Date
2014-03-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
87
Registration Number
NCT01683396

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Phase 2
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Placebo
Drug: gevokizumab
First Posted Date
2011-12-26
Last Posted Date
2014-03-04
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
127
Registration Number
NCT01498874
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy